{
  "meta": {
    "title": "18_Clinical_Trials_Miscellaneous",
    "url": "https://brainandscalpel.vercel.app/18-clinical-trials-miscellaneous-f590f5fc.html",
    "scrapedAt": "2025-11-30T06:59:44.480Z"
  },
  "questions": [
    {
      "id": 79810,
      "choices": [
        {
          "id": 247078,
          "text": "Right drug"
        },
        {
          "id": 247079,
          "text": "Right doctor"
        },
        {
          "id": 247080,
          "text": "Right patient"
        },
        {
          "id": 247081,
          "text": "Right route"
        }
      ],
      "text": "Following are “rights” of safe medication except",
      "unique_key": "Q6207787",
      "question_audio": null,
      "question_video": null,
      "map_id": 34348741,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Right Doctor The \"Rights\" of Safe Medication Administration are a set of essential principles aimed at minimizing medication errors and ensuring patient safety. The five traditional rights include: Right Drug – Ensuring the correct medication is administered. Right Patient – Verifying the identity of the patient to prevent errors. Right Dose – Administering the correct dosage to avoid under- or overdosing. Right Route – Ensuring the medication is given via the correct administration route (e.g., oral, intravenous, intramuscular). Right Time – Administering the drug at the prescribed time to maintain therapeutic effectiveness. Some models extend these to ten rights, adding aspects like right documentation, right reason, right response, and right to refuse. The \"Right Doctor\" is not included in these safety principles, as the focus is on ensuring the correct administration of medication rather than the prescriber. Hence, option B is the correct answer. Incorrect Options: A) Right Drug – Incorrect This is a fundamental principle ensuring that the prescribed medication matches the intended treatment plan. Verifying the name, formulation, and expiry date of the drug prevents medication errors. Since administering the right drug is crucial for safe medication practice, this option is incorrect. C) Right Patient – Incorrect Ensuring that the medication is given to the correct patient prevents dangerous mix-ups, especially in settings where multiple patients receive similar treatments. Double-checking patient identity using name, date of birth, or ID wristbands is standard practice in hospitals. Since confirming the right patient is essential for safe medication, this option is incorrect. D) Right Route – Incorrect Medications must be administered via the correct route to ensure efficacy and avoid harm. Some drugs can be toxic if given via the wrong route (e.g., IV potassium chloride instead of oral). Since choosing the right route is a key aspect of medication safety, this option is incorrect.",
      "correct_choice_id": 247079,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19278741700310209/19278741700310209.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/19278741700310209/19278741700310209.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79811,
      "choices": [
        {
          "id": 247082,
          "text": "Clearance"
        },
        {
          "id": 247083,
          "text": "Plasma concentrations"
        },
        {
          "id": 247084,
          "text": "Rate of elimination"
        },
        {
          "id": 247085,
          "text": "All of the above"
        }
      ],
      "text": "Half-life is directly proportional to",
      "unique_key": "Q2124185",
      "question_audio": null,
      "question_video": null,
      "map_id": 34186295,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Plasma Concentrations The half-life (t½) of a drug is the time required for its plasma concentration to reduce by 50%. It is determined by the drug’s volume of distribution (Vd) While half-life is primarily influenced by volume of distribution and clearance, it is also directly proportional to plasma drug concentration in zero-order kinetics. In drugs exhibiting zero-order elimination (e.g., phenytoin, alcohol, aspirin at high doses), elimination is constant regardless of plasma concentration, leading to an increase in half-life as plasma concentration rises. Thus, option B is correct because, in drugs with zero-order kinetics, half-life increases with higher plasma concentrations due to saturation of elimination pathways. Incorrect Options: A) Clearance – Incorrect Clearance (CL) is inversely proportional to half-life, Increased clearance leads to a shorter half-life, while reduced clearance (e.g., in kidney or liver disease) prolongs half-life. Since half-life is inversely, not directly, proportional to clearance, this option is incorrect. C) Rate of Elimination – Incorrect Rate of elimination (ROE) = Clearance × Plasma concentration In first-order kinetics, elimination is proportional to drug concentration, but half-life remains constant. In zero-order kinetics, elimination is constant, but half-life increases at high concentrations. Since half-life is not directly proportional to the rate of elimination in most cases, this option is incorrect. D) All of the Above – Incorrect Since half-life is not directly proportional to clearance or rate of elimination, this option is incorrect.",
      "correct_choice_id": 247083,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29559661700310312/29559661700310312.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29559661700310312/29559661700310312.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79812,
      "choices": [
        {
          "id": 247086,
          "text": "Weakly acidic drugs"
        },
        {
          "id": 247087,
          "text": "Both"
        },
        {
          "id": 247088,
          "text": "Weakly basic drugs"
        },
        {
          "id": 247089,
          "text": "None of the above"
        }
      ],
      "text": "At fetal plasma, drugs showing ion trapping are",
      "unique_key": "Q7470533",
      "question_audio": null,
      "question_video": null,
      "map_id": 34223094,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Weakly Basic Drugs Ion trapping occurs when a drug becomes ionized in a specific body compartment due to differences in pH, preventing it from crossing membranes easily and leading to its accumulation in that compartment. Fetal plasma is more acidic (pH ~7.3) compared to maternal plasma (pH ~7.4). Weakly basic drugs (e.g., lidocaine, morphine) remain non-ionized in maternal plasma, allowing them to cross the placenta easily. Once in the more acidic fetal plasma, weak bases become ionized (BH+ form), reducing their ability to diffuse back to the maternal circulation, leading to accumulation in fetal circulation (ion trapping). This mechanism can increase fetal drug exposure and potential toxicity. Thus, weakly basic drugs undergo ion trapping in fetal plasma, making option C the correct answer. Incorrect Options: A) Weakly Acidic Drugs – Incorrect Weakly acidic drugs (e.g., aspirin, warfarin) are more non-ionized in acidic environments and become ionized in more alkaline conditions. Since fetal plasma is more acidic than maternal plasma, weak acids remain mostly non-ionized and do not undergo significant ion trapping. Since weakly acidic drugs do not get trapped in fetal plasma, this option is incorrect. B) Both – Incorrect Only weakly basic drugs undergo ion trapping in fetal plasma due to pH differences. Weakly acidic drugs do not accumulate in the fetal circulation. Since only weakly basic drugs undergo ion trapping, this option is incorrect. D) None of the Above – Incorrect Weakly basic drugs do undergo ion trapping, so this option is incorrect.",
      "correct_choice_id": 247088,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1801131700310323/1801131700310323.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1801131700310323/1801131700310323.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79813,
      "choices": [
        {
          "id": 247090,
          "text": "An antihypertensive with a plasma half-life of 3 hours"
        },
        {
          "id": 247091,
          "text": "An anti-arrhythmic drug with a plasma half-life of 10 seconds used for acute treatment of PSVT"
        },
        {
          "id": 247092,
          "text": "An anti-inflammatory drug with a plasma half-life of 24 hour"
        },
        {
          "id": 247093,
          "text": "A hypnotic drug with a plasma half-life of 2 hours"
        }
      ],
      "text": "Which of the following drugs should be given in sustained release oral dosage form",
      "unique_key": "Q9877283",
      "question_audio": null,
      "question_video": null,
      "map_id": 34447010,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) An antihypertensive with a plasma half-life of 3 hours Sustained-release (SR) oral dosage forms are designed to prolong drug action and reduce dosing frequency, making them ideal for drugs that: Have a short-to-moderate half-life (2–6 hours) Require consistent plasma drug levels for therapeutic effects Are used for chronic conditions, such as hypertension An antihypertensive drug with a plasma half-life of 3 hours fits these criteria well. If given in an immediate-release form, it would require frequent dosing (e.g., every 4–6 hours) to maintain therapeutic levels. Using an SR formulation: Ensures steady drug release and effect Improves patient compliance Reduces fluctuations in plasma concentration Thus, option A is correct. Incorrect Options: B) An anti-arrhythmic drug with a plasma half-life of 10 seconds used for acute treatment of PSVT – Incorrect A drug with a half-life of 10 seconds (e.g., adenosine) acts very rapidly and is used for acute conditions like paroxysmal supraventricular tachycardia (PSVT). Sustained-release formulations are unnecessary for emergency drugs because their effects are needed immediately, and they are given as IV bolus injections. Since SR formulation would delay drug onset and reduce effectiveness, this option is incorrect. C) An anti-inflammatory drug with a plasma half-life of 24 hours – Incorrect A drug with a long half-life (~24 hours) naturally maintains therapeutic levels for extended periods without the need for sustained release. SR formulations are unnecessary for long half-life drugs because a single daily dose is usually sufficient. Example: Meloxicam (t½ ~ 24 hours) is given once daily without SR formulation. Since SR formulation offers no significant advantage here, this option is incorrect. D) A hypnotic drug with a plasma half-life of 2 hours – Incorrect Hypnotics (e.g., benzodiazepines, Z-drugs) are used for short-term effects, like inducing sleep. Sustained-release formulations would prolong drug action, leading to next-day sedation (\"hangover effect\"). Example: Zolpidem (t½ ~2 hours) is used for sleep initiation, and extended-release forms are used only when necessary. Since SR formulation could cause residual sedation and impair function, this option is incorrect.",
      "correct_choice_id": 247090,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1170561700310356/1170561700310356.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/1170561700310356/1170561700310356.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79814,
      "choices": [
        {
          "id": 247094,
          "text": "It is a drug which acts on orphanin receptors"
        },
        {
          "id": 247095,
          "text": "It is a very cheap drug"
        },
        {
          "id": 247096,
          "text": "It is a drug required for treatment or prevention of a rare disease"
        },
        {
          "id": 247097,
          "text": "It is a drug which has no therapeutic use"
        }
      ],
      "text": "Which of the following statements best describes an ‘orphan drug’",
      "unique_key": "Q4545506",
      "question_audio": null,
      "question_video": null,
      "map_id": 34827588,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) It is a drug required for the treatment or prevention of a rare disease An orphan drug is a pharmaceutical agent developed specifically to treat, prevent, or diagnose a rare disease (also called an orphan disease). Rare diseases affect a small percentage of the population, making drug development economically unviable for pharmaceutical companies due to the limited market. To encourage research and development of such drugs, various regulatory agencies (e.g., FDA Orphan Drug Act in the U.S., EMA in Europe) provide incentives like: Tax credits for clinical trials Grant funding Market exclusivity for a specific period (e.g., 7 years in the U.S.) Examples of orphan drugs include: Ivacaftor for cystic fibrosis Eculizumab for paroxysmal nocturnal hemoglobinuria Nusinersen for spinal muscular atrophy Since orphan drugs are specifically developed for rare diseases, option C is correct. Incorrect Options: A) It is a drug which acts on orphanin receptors – Incorrect Orphanin receptors (e.g., opioid receptor-like 1 - ORL1) bind endogenous neuropeptides like nociceptin/orphanin FQ, which regulate pain, mood, and learning. These receptors have no direct connection to the term \"orphan drug\", which refers to drugs for rare diseases. Since this statement confuses orphan drugs with orphanin receptors, it is incorrect. B) It is a very cheap drug – Incorrect Many orphan drugs are very expensive due to limited production, specialized research, and small patient populations. Example: Zolgensma (gene therapy for spinal muscular atrophy) costs ~$2.1 million per dose, making it one of the most expensive drugs in the world. Since orphan drugs are often costly rather than cheap, this option is incorrect. D) It is a drug which has no therapeutic use – Incorrect Orphan drugs have therapeutic use in rare diseases. The only reason they are called \"orphan\" drugs is because pharmaceutical companies often neglect them due to low commercial viability. Since orphan drugs do have therapeutic applications, this option is incorrect.",
      "correct_choice_id": 247096,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7542391700310369/7542391700310369.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/7542391700310369/7542391700310369.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79815,
      "choices": [
        {
          "id": 247098,
          "text": "Placebo is the inert material added to the drug for making tablets"
        },
        {
          "id": 247099,
          "text": "Placebo do not produce any effect"
        },
        {
          "id": 247100,
          "text": "All patients respond to placebo"
        },
        {
          "id": 247101,
          "text": "Placebo is a dummy medication"
        }
      ],
      "text": "Which of the following is true of ‘placebo’",
      "unique_key": "Q9913573",
      "question_audio": null,
      "question_video": null,
      "map_id": 34122336,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Placebo is a dummy medication A placebo is a pharmacologically inert substance (e.g., sugar pill, saline injection) that resembles an active drug but has no therapeutic effect. It is commonly used in clinical trials to compare the effects of a new drug against a non-active treatment. Placebos help determine a drug’s true effectiveness by ruling out psychological effects where patients improve simply because they believe they are receiving treatment (placebo effect). In double-blind studies, neither the patient nor the researcher knows who is receiving the placebo, reducing bias. Though placebos lack active ingredients, they can still induce physiological responses (e.g., reduced pain, improved mood) due to the placebo effect. Since placebo is a dummy medication used in clinical trials and research, option D is correct. Incorrect Options: A) Placebo is the inert material added to the drug for making tablets – Incorrect Inactive excipients (e.g., fillers, binders) are added to drugs to aid in tablet formulation but are not considered placebos. Placebos are standalone dummy medications used in research, whereas excipients are part of an actual drug formulation. Since this confuses excipients with placebos, this option is incorrect. B) Placebo does not produce any effect – Incorrect While placebos lack active pharmacological effects, they can still produce real physiological or psychological changes due to the placebo effect. Patients taking a placebo often report pain relief, reduced anxiety, or symptom improvement purely because they expect the treatment to work. Since placebos can indirectly produce effects through psychological mechanisms, this option is incorrect. C) All patients respond to placebo – Incorrect The placebo effect varies among individuals, with some patients showing a strong response and others none at all. Factors influencing the placebo effect include patient expectations, belief in treatment, and neurological factors (dopamine, endorphins). Since not all patients respond to placebo, this option is incorrect.",
      "correct_choice_id": 247101,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37358821700310381/37358821700310381.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/37358821700310381/37358821700310381.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79816,
      "choices": [
        {
          "id": 247102,
          "text": "Determination of plasma level of these drugs is quite tedious and long process"
        },
        {
          "id": 247103,
          "text": "Antihypertensive effect does not increase linearly with the dose"
        },
        {
          "id": 247104,
          "text": "All antihypertensive drugs are prodrugs"
        },
        {
          "id": 247105,
          "text": "It is easier to measure the effect of these drugs"
        }
      ],
      "text": "Therapeutic drug monitoring of plasma concentrations of antihypertensive drugs are not practiced because",
      "unique_key": "Q8561314",
      "question_audio": null,
      "question_video": null,
      "map_id": 34901691,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It is easier to measure the effect of these drugs Therapeutic drug monitoring (TDM) involves measuring plasma drug concentrations to optimize dosing and prevent toxicity. However, TDM is not routinely practiced for antihypertensive drugs because blood pressure (BP) can be directly measured, providing an easy and reliable assessment of drug efficacy. BP measurement using sphygmomanometers or ambulatory BP monitors gives an immediate indication of the drug’s effect, making plasma concentration monitoring unnecessary. The desired therapeutic goal of antihypertensive drugs is to maintain target BP levels, which can be easily tracked and adjusted based on clinical response rather than plasma levels. Unlike drugs with a narrow therapeutic index (e.g., digoxin, lithium, aminoglycosides), where plasma monitoring is crucial to avoid toxicity, antihypertensives generally have a wider safety margin, reducing the need for routine TDM. Since measuring BP is a simple and direct method to assess drug efficacy, option D is correct. Incorrect Options: A) Determination of plasma level of these drugs is quite tedious and long process – Incorrect While measuring plasma concentrations of antihypertensive drugs can be complex, this is not the primary reason for avoiding TDM. Many drugs requiring TDM (e.g., anticonvulsants, immunosuppressants) also have complex assays but are still monitored due to narrow therapeutic windows. Since the main reason is the ease of measuring BP rather than assay complexity, this option is incorrect. B) Antihypertensive effect does not increase linearly with the dose – Incorrect Many antihypertensive drugs, particularly beta-blockers and calcium channel blockers, show a non-linear dose-response relationship, meaning higher doses do not always proportionally increase BP reduction. However, this is not the main reason for avoiding TDM, as many non-linearly acting drugs (e.g., phenytoin) still require monitoring. Since TDM is avoided because BP is directly measurable, not due to dose-response non-linearity, this option is incorrect. C) All antihypertensive drugs are prodrugs – Incorrect Not all antihypertensive drugs are prodrugs. While some (e.g., enalapril, losartan) require metabolic activation, many (e.g., amlodipine, atenolol, hydrochlorothiazide) are active in their administered form. Since this statement is factually incorrect, this option is incorrect.",
      "correct_choice_id": 247105,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78562381700310394/78562381700310394.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78562381700310394/78562381700310394.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79817,
      "choices": [
        {
          "id": 247106,
          "text": "Drug B is less efficacious than drug A"
        },
        {
          "id": 247107,
          "text": "Drug A is safer drug than drug B"
        },
        {
          "id": 247108,
          "text": "Drug A will have shorter duration of action than drug"
        },
        {
          "id": 247109,
          "text": "Drug A is more potent than drug B"
        }
      ],
      "text": "A 56-year-old man, Surender with heart failure is to be treated with a diuretic drug. Drugs A and B have same mechanism of action. Drug A in dose of 50 mg produces the same magnitude of diuresis as 500 mg of drug B. This suggests that",
      "unique_key": "Q5468776",
      "question_audio": null,
      "question_video": null,
      "map_id": 34886107,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Drug A is more potent than Drug B Potency refers to the amount of drug required to produce a given effect. A drug is considered more potent if a lower dose is required to achieve the same therapeutic effect as another drug with the same mechanism of action. In this case, Drug A (50 mg) produces the same diuretic effect as Drug B (500 mg). Since a lower dose of Drug A is required for the same effect, it is more potent than Drug B. Potency is a measure of drug concentration or dose, not its maximum effect (efficacy). Thus, Drug A is more potent than Drug B, making option D correct. Incorrect Options: A) Drug B is less efficacious than Drug A – Incorrect Efficacy refers to the maximum effect a drug can produce, regardless of dose. Since both drugs produce the same diuretic effect, their efficacy is the same. The difference lies in the dose required, not in the maximum effect. Thus, this option is incorrect. B) Drug A is a safer drug than Drug B – Incorrect Potency does not determine safety. A more potent drug is not necessarily safer—it just requires a lower dose to achieve the same effect. Drug safety depends on factors like therapeutic index (TI), side effects, and toxicity profile, not potency. A highly potent drug can still have narrow safety margins and cause toxicity at low doses. Thus, potency alone does not determine safety, making this option incorrect. C) Drug A will have a shorter duration of action than Drug B – Incorrect The duration of action of a drug is determined by pharmacokinetics, such as half-life, metabolism, and elimination, not potency. More potent drugs can have short or long durations of action depending on how they are metabolized and excreted. There is no direct relationship between potency and duration of action. Since potency does not determine how long a drug lasts in the body, this option is incorrect.",
      "correct_choice_id": 247109,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29152221700310466/29152221700310466.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29152221700310466/29152221700310466.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79818,
      "choices": [
        {
          "id": 247110,
          "text": "Highly selective drug"
        },
        {
          "id": 247111,
          "text": "Highly potent cardiac stimulant"
        },
        {
          "id": 247112,
          "text": "Highly efficacious bronchodilator"
        },
        {
          "id": 247113,
          "text": "Highly toxic drug"
        }
      ],
      "text": "Dose response curves of salbutamol for bronchodilation and tachycardia are widely separated in the dose axis. This information suggests that salbutamol is",
      "unique_key": "Q2193725",
      "question_audio": null,
      "question_video": null,
      "map_id": 34074828,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Highly selective drug The dose-response curve (DRC) of salbutamol for bronchodilation and tachycardia being widely separated on the dose axis indicates that different doses are required to produce these effects. Salbutamol is a β2-adrenergic receptor agonist, primarily acting on bronchial smooth muscle to cause bronchodilation. It has less affinity for β1-adrenergic receptors in the heart, meaning that at therapeutic doses, it mainly dilates the airways with minimal cardiac stimulation. The wide separation in the DRCs suggests that bronchodilation occurs at a much lower dose than tachycardia, meaning salbutamol preferentially activates β2 receptors while sparing β1 receptors at usual doses. This property is called \"high selectivity\", making option A the correct answer. Incorrect Options: B) Highly potent cardiac stimulant – Incorrect If salbutamol were a highly potent cardiac stimulant, its tachycardia DRC would be much closer to its bronchodilation DRC. Since the dose required for tachycardia is much higher than for bronchodilation, it suggests low cardiac stimulation, not high potency. C) Highly efficacious bronchodilator – Incorrect Efficacy refers to the maximum effect a drug can produce, while potency refers to the dose required to produce an effect. The given information only describes dose separation (potency differences), not whether salbutamol achieves maximal bronchodilation. Therefore, we cannot conclude its efficacy from this data alone. D) Highly toxic drug – Incorrect A drug is considered highly toxic if it causes significant adverse effects at therapeutic doses. Since salbutamol shows a large dose difference between bronchodilation and tachycardia, it means that therapeutic doses are safe, and toxicity only occurs at much higher doses. This suggests low toxicity at normal doses, not high toxicity.",
      "correct_choice_id": 247110,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76544261700310518/76544261700310518.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/76544261700310518/76544261700310518.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79819,
      "choices": [
        {
          "id": 247114,
          "text": "Primaquine induced hemolytic anemia"
        },
        {
          "id": 247115,
          "text": "Hypoglycemia by insulin"
        },
        {
          "id": 247116,
          "text": "Tachycardia by albuterol"
        },
        {
          "id": 247117,
          "text": "Metoclopramide induced muscle dystonia"
        }
      ],
      "text": "Which of the following is most likely due to a pharmacogenetics condition",
      "unique_key": "Q3125866",
      "question_audio": null,
      "question_video": null,
      "map_id": 34577102,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Primaquine-induced hemolytic anemia Primaquine-induced hemolytic anemia is a classic example of a pharmacogenetic condition. This occurs due to a deficiency of glucose-6-phosphate dehydrogenase (G6PD), an enzyme essential for protecting red blood cells from oxidative stress. Individuals with G6PD deficiency have reduced ability to neutralize reactive oxygen species (ROS). Primaquine, an antimalarial drug, induces oxidative stress, leading to hemolysis (destruction of red blood cells) in G6PD-deficient individuals. This genetic disorder follows an X-linked recessive pattern, making it more common in males. Since this adverse reaction is directly linked to an inherited genetic trait, it is a pharmacogenetic condition, making option A the correct answer. Incorrect Options: B) Hypoglycemia by insulin – Incorrect Hypoglycemia is a pharmacodynamic effect of insulin due to its expected mechanism of action (lowering blood glucose levels). It is not caused by genetic variations but rather by dose, diet, or patient compliance. Therefore, it does not classify as a pharmacogenetic condition. C) Tachycardia by albuterol – Incorrect Albuterol is a β2-adrenergic agonist used for bronchodilation. It can cause tachycardia as a side effect due to β1 receptor activation in the heart. This is a pharmacological response, not a genetic predisposition, so it does not fall under pharmacogenetics. D) Metoclopramide-induced muscle dystonia – Incorrect Metoclopramide is a dopamine antagonist that can cause extrapyramidal side effects (EPS), including acute dystonia. While some genetic variations in dopaminergic pathways may increase susceptibility, metoclopramide-induced dystonia is primarily a pharmacological adverse reaction, not a well-established pharmacogenetic disorder.",
      "correct_choice_id": 247114,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8289721700310529/8289721700310529.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/8289721700310529/8289721700310529.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79820,
      "choices": [
        {
          "id": 247118,
          "text": "Phase II"
        },
        {
          "id": 247119,
          "text": "Phase III"
        },
        {
          "id": 247120,
          "text": "Phase IV"
        },
        {
          "id": 247121,
          "text": "Phase I"
        }
      ],
      "text": "Evaluation of safety and tolerability in humans using maximum tolerated dose (MTD) as end point is done in",
      "unique_key": "Q4327114",
      "question_audio": null,
      "question_video": null,
      "map_id": 34256771,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Phase I – Correct Phase I clinical trials are primarily conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug in healthy volunteers or, in some cases, patients (e.g., cancer drugs). One of the key objectives of Phase I trials is to determine the Maximum Tolerated Dose (MTD), which is the highest dose that can be administered without causing unacceptable toxicity. The dose-escalation method is often used to gradually increase the dose until dose-limiting toxicities (DLTs) are observed. Other important endpoints in Phase I trials include drug metabolism, absorption, distribution, and excretion (ADME), and early signs of efficacy. Thus, since MTD determination is a key aspect of Phase I trials, the correct answer is (D) Phase I. Incorrect Options Explained: (A) Phase II – Incorrect Phase II trials focus on efficacy in patients and further evaluate safety. These trials determine the optimal dose and therapeutic window, but they do not primarily aim to establish the Maximum Tolerated Dose (MTD). Typically, Phase II studies involve a larger patient population than Phase I trials and are divided into Phase IIa (dose-finding) and Phase IIb (efficacy confirmation). (B) Phase III – Incorrect Phase III trials are large-scale randomized controlled trials (RCTs) that confirm the efficacy and safety of the drug in a broader patient population. They compare the new drug with existing standard treatments to establish superiority or non-inferiority. The focus is on clinical benefit, long-term safety, and side effects rather than determining MTD. (C) Phase IV – Incorrect Phase IV (Post-Marketing Surveillance) studies occur after drug approval and focus on long-term safety, rare adverse effects, and real-world effectiveness. These studies help in identifying rare or delayed adverse effects and are not concerned with dose escalation or MTD determination.",
      "correct_choice_id": 247121,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71667421700311221/71667421700311221.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/71667421700311221/71667421700311221.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79821,
      "choices": [
        {
          "id": 247122,
          "text": "Type A"
        },
        {
          "id": 247123,
          "text": "Type E"
        },
        {
          "id": 247124,
          "text": "Type B"
        },
        {
          "id": 247125,
          "text": "Type D"
        }
      ],
      "text": "Rebound hypertension after clonidine withdrawal is following type of ADR",
      "unique_key": "Q3920746",
      "question_audio": null,
      "question_video": null,
      "map_id": 34404455,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Type E – Correct Rebound hypertension after clonidine withdrawal is classified as a Type E (End-of-use) adverse drug reaction (ADR). Type E ADRs occur when a drug is abruptly discontinued, leading to withdrawal effects. Clonidine, an alpha-2 adrenergic agonist, suppresses sympathetic outflow, reducing blood pressure. When clonidine is suddenly stopped, there is a sudden surge of catecholamines, leading to a rapid increase in blood pressure (rebound hypertension). To prevent this, clonidine should be tapered gradually rather than stopped abruptly. Thus, since withdrawal effects fall under Type E ADRs, the correct answer is (B) Type E. Incorrect Options Explained: (A) Type A – Incorrect Type A (Augmented) ADRs are dose-dependent and result from the exaggeration of a drug’s known pharmacological effects. Example: Hypotension due to excessive clonidine dose. Rebound hypertension is not due to excessive drug action but rather withdrawal, so it does not belong to Type A ADRs. (C) Type B – Incorrect Type B (Bizarre) ADRs are unpredictable, uncommon, and not related to the drug’s known mechanism of action. These reactions often include idiosyncratic or allergic responses. Example: Anaphylaxis due to penicillin. Rebound hypertension is predictable and related to the drug’s mechanism, so it is not Type B. (D) Type D – Incorrect Type D (Delayed) ADRs occur long after drug exposure, sometimes even after stopping the drug. Example: Carcinogenesis after chemotherapy, teratogenic effects of thalidomide. Rebound hypertension occurs immediately after withdrawal, so it does not fit Type D ADRs.",
      "correct_choice_id": 247123,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64777371700311232/64777371700311232.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/64777371700311232/64777371700311232.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79822,
      "choices": [
        {
          "id": 247126,
          "text": "Are essential for lifestyle modification"
        },
        {
          "id": 247127,
          "text": "Treat only epidemic diseases"
        },
        {
          "id": 247128,
          "text": "Are newer in the market"
        },
        {
          "id": 247129,
          "text": "Satisfy the priority health care needs"
        }
      ],
      "text": "Essentials Medicines are those that",
      "unique_key": "Q9976526",
      "question_audio": null,
      "question_video": null,
      "map_id": 34765793,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Satisfy the priority health care needs – Correct Essential medicines are those that meet the most important healthcare needs of a population. They are selected based on efficacy, safety, cost-effectiveness, and public health relevance. The World Health Organization (WHO) maintains the Model List of Essential Medicines, which serves as a guide for countries to develop their own national lists. Essential medicines should be available in adequate amounts, in appropriate dosage forms, and at an affordable price. They are used to treat a wide range of conditions, from infectious diseases, chronic illnesses, and maternal health issues to emergency care. Thus, the correct answer is (D) because essential medicines address the priority healthcare needs of a population. Incorrect Options Explained: (A) Are essential for lifestyle modification – Incorrect Lifestyle modification involves changes in diet, exercise, and habits rather than medications. While some drugs may support lifestyle changes (e.g., statins for high cholesterol), essential medicines are defined by their impact on public health, not lifestyle modification alone. (B) Treat only epidemic diseases – Incorrect Essential medicines include drugs for both infectious diseases (e.g., antibiotics, antivirals) and chronic diseases (e.g., insulin for diabetes, antihypertensives). While some essential medicines are used to manage epidemics (e.g., antimalarials, antivirals for HIV/AIDS), they are not limited to epidemics alone. (C) Are newer in the market – Incorrect Essential medicines are not chosen based on how new they are but based on effectiveness, safety, and public health importance. Many older, well-established drugs (e.g., aspirin, amoxicillin) remain essential because of their proven benefits and affordability.",
      "correct_choice_id": 247129,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26467591700311250/26467591700311250.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26467591700311250/26467591700311250.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79823,
      "choices": [
        {
          "id": 247130,
          "text": "Active drug to inactive metabolite"
        },
        {
          "id": 247131,
          "text": "Inactive drug to active metabolite"
        },
        {
          "id": 247132,
          "text": "Active drug to active metabolite"
        },
        {
          "id": 247133,
          "text": "Active drug toxic metabolite"
        }
      ],
      "text": "Conversion of Diazepam to Oxazepam is an example of",
      "unique_key": "Q3902507",
      "question_audio": null,
      "question_video": null,
      "map_id": 34400293,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Active drug to active metabolite – Correct The conversion of diazepam to oxazepam is an example of an active drug being metabolized into another active metabolite. Diazepam (a benzodiazepine) undergoes hepatic metabolism, primarily by CYP enzymes, to form desmethyldiazepam, temazepam, and oxazepam—all of which are pharmacologically active. Oxazepam itself is a short-acting benzodiazepine with sedative, anxiolytic, and muscle relaxant properties. This process prolongs the overall effect of diazepam, as its active metabolites continue exerting their pharmacological actions before final elimination. Thus, since both diazepam and oxazepam are active, this is a classic example of an \"active drug to active metabolite\" transformation, making (C) the correct choice. Incorrect Options Explained: (A) Active drug to inactive metabolite – Incorrect If diazepam were converted to an inactive form, it would no longer produce an effect. However, oxazepam remains pharmacologically active, meaning this option is incorrect. (B) Inactive drug to active metabolite – Incorrect This scenario refers to prodrugs, where an inactive compound (prodrug) is converted into an active drug. Diazepam is already active, meaning it does not need activation. Therefore, this option does not apply here. (D) Active drug to toxic metabolite – Incorrect Some drugs are metabolized into toxic metabolites (e.g., paracetamol to NAPQI), which can cause harm. Oxazepam is not a toxic metabolite; it retains therapeutic activity. Since it remains clinically useful, this option is incorrect.",
      "correct_choice_id": 247132,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48570331700311264/48570331700311264.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/48570331700311264/48570331700311264.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79824,
      "choices": [
        {
          "id": 247134,
          "text": "CYP2D6"
        },
        {
          "id": 247135,
          "text": "CYP2C19"
        },
        {
          "id": 247136,
          "text": "CYP2C9"
        },
        {
          "id": 247137,
          "text": "UGT1A1"
        }
      ],
      "text": "A 7-year-old child is brought to the emergency department in coma with cyanosis. Her mother states that the girl was given codeine with paracetamol because of severe bruising after a fall. Shortly after the first dose, the child became unresponsive and “turned blue.” Which of the following alleles might be responsible for this presentation?",
      "unique_key": "Q2535462",
      "question_audio": null,
      "question_video": null,
      "map_id": 34441908,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) CYP2D6. CYP2D6 is a cytochrome P450 enzyme responsible for the metabolism of codeine into its active metabolite, morphine. Codeine itself has minimal analgesic effects, but when metabolized by CYP2D6, it is converted to morphine, which provides pain relief. However, genetic polymorphisms of CYP2D6 can lead to ultrarapid metabolism, causing excessive conversion of codeine into morphine, leading to opioid toxicity. In this case, the child likely has a CYP2D6 ultrarapid metabolizer (UM) phenotype, which results in dangerously high levels of morphine after a standard dose of codeine. This causes respiratory depression, cyanosis, and coma, which are typical signs of opioid overdose. Explanation of Incorrect Options: (B) CYP2C19 – Incorrect. CYP2C19 is primarily involved in the metabolism of proton pump inhibitors (PPIs), clopidogrel, and certain antidepressants (e.g., diazepam, citalopram). It is not responsible for codeine metabolism and does not cause opioid toxicity. (C) CYP2C9 – Incorrect. CYP2C9 metabolizes drugs like warfarin, phenytoin, and NSAIDs (e.g., ibuprofen, diclofenac). Genetic variations in CYP2C9 can alter drug clearance, but they do not affect codeine metabolism or lead to opioid toxicity. (D) UGT1A1 – Incorrect. UGT1A1 (Uridine diphosphate glucuronosyltransferase 1A1) is involved in the metabolism and conjugation of bilirubin and certain drugs like irinotecan. Mutations in UGT1A1 cause Gilbert syndrome and Crigler-Najjar syndrome, but it has no role in codeine metabolism or opioid toxicity.",
      "correct_choice_id": 247134,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25781561700305191/25781561700305191.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/25781561700305191/25781561700305191.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79825,
      "choices": [
        {
          "id": 247138,
          "text": "Golgi apparatus"
        },
        {
          "id": 247139,
          "text": "Smooth endoplasmic reticulum"
        },
        {
          "id": 247140,
          "text": "Mitochondria"
        },
        {
          "id": 247141,
          "text": "Peroxisomes"
        }
      ],
      "text": "Researchers interested in studying a certain cytochrome P450 enzyme wish to isolate the enzyme of interest from the many other proteins in the cells. One of their initial steps is to lyse the cells and isolate the organelle which carries the enzyme they want to study. Which organelle will they isolate to find CYP enzymes?",
      "unique_key": "Q4148073",
      "question_audio": null,
      "question_video": null,
      "map_id": 34267974,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Smooth Endoplasmic Reticulum Explanation for the Correct Answer: Cytochrome P450 (CYP) enzymes are a superfamily of heme-containing enzymes primarily involved in drug metabolism, steroid synthesis, and detoxification. The majority of CYP enzymes are membrane-bound and localized in the smooth endoplasmic reticulum (SER), particularly in the liver, which is the major site of drug metabolism. Function of CYP enzymes in the SER: They participate in phase I metabolism of drugs by oxidation, reduction, and hydrolysis, making compounds more polar for further metabolism or excretion. They play a crucial role in the synthesis of steroid hormones, bile acids, and cholesterol metabolism. The liver contains a high concentration of SER, making it the main site of CYP enzyme activity. Since the researchers are looking to isolate a cytochrome P450 enzyme, they should isolate the smooth endoplasmic reticulum (SER), where the majority of CYP enzymes are found. Explanation for the Incorrect Answers: (A) Golgi apparatus The Golgi apparatus is responsible for protein modification, packaging, and transport, but it does not house cytochrome P450 enzymes. It is primarily involved in glycosylation and protein sorting, not in drug metabolism or detoxification. Therefore, this option is incorrect. (C) Mitochondria Some CYP enzymes (e.g., CYP11A1, CYP11B1, CYP11B2) are found in mitochondria, particularly in steroidogenic tissues (e.g., adrenal glands, testes, and ovaries), where they help in steroid hormone biosynthesis. However, the majority of CYP enzymes, especially those involved in drug metabolism (e.g., CYP3A4, CYP2D6), are located in the SER, not mitochondria. Since the question does not specify steroid metabolism, this option is not the best choice. (D) Peroxisomes Peroxisomes are involved in β-oxidation of very long-chain fatty acids, hydrogen peroxide metabolism, and lipid metabolism, but they do not contain cytochrome P450 enzymes in significant amounts. CYP enzymes are not primarily located in peroxisomes, making this an incorrect answer.",
      "correct_choice_id": 247139,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23482511700306105/23482511700306105.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23482511700306105/23482511700306105.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79826,
      "choices": [
        {
          "id": 247142,
          "text": "Bicarbonate should not have been given; a weak acid such as ammonium chloride should have been given instead"
        },
        {
          "id": 247143,
          "text": "Bicarbonate traps amitriptyline in the blood to keep it from reaching its active site"
        },
        {
          "id": 247144,
          "text": "Ion trapping the amitriptyline in the urine to hasten elimination is accomplished by giving bicarbonate"
        },
        {
          "id": 247145,
          "text": "Weak acids such as amitriptyline are chemically inactivated by bicarbonate"
        }
      ],
      "text": "On your emergency duty a concerned mother brought her 4 year old son. She tells you that her son ate a handful of her amitriptyline (a weak acid). At emergency department the child is given bicarbonate (in addition to other measures). What is the most likely explanation for bicarbonate administration in this case?",
      "unique_key": "Q2581031",
      "question_audio": null,
      "question_video": null,
      "map_id": 34136613,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ion trapping the amitriptyline in the urine to hasten elimination is accomplished by giving bicarbonate Explanation for the Correct Answer: Amitriptyline is a tricyclic antidepressant (TCA) that is a weak base. In cases of TCA overdose, sodium bicarbonate is administered to alkalinize the urine, which promotes ion trapping and enhances drug elimination. Mechanism of ion trapping: Amitriptyline exists in two forms: protonated (charged, BH*) and unprotonated (uncharged, B). In an alkaline environment (high pH, caused by bicarbonate administration), amitriptyline remains in its uncharged form in the blood, which reduces its toxic effects on cardiac sodium channels. In the renal tubules, the alkaline pH converts the drug into its ionized (BH*) form, trapping it in the urine and preventing reabsorption into the bloodstream. This enhances renal clearance and promotes faster elimination of amitriptyline, helping to mitigate toxicity. Thus, administering bicarbonate helps in the elimination of amitriptyline via urinary ion trapping, making option (C) the correct answer. Explanation for the Incorrect Answers: (A) Bicarbonate should not have been given; a weak acid such as ammonium chloride should have been given instead This statement is incorrect because amitriptyline is a weak base, not a weak acid. Ammonium chloride would acidify the urine, which would actually increase reabsorption of amitriptyline, worsening the toxicity. Instead, alkalizing the urine with bicarbonate enhances drug elimination, making this choice incorrect. (B) Bicarbonate traps amitriptyline in the blood to keep it from reaching its active site Sodium bicarbonate does not trap the drug in the blood; rather, it enhances drug elimination by ion trapping in the urine. Additionally, bicarbonate reduces cardiotoxicity by stabilizing cardiac sodium channels, but it does not \"trap\" the drug in circulation. This explanation does not correctly describe the mechanism, making it incorrect. (D) Weak acids such as amitriptyline are chemically inactivated by bicarbonate Amitriptyline is not a weak acid; it is a weak base. Bicarbonate does not chemically inactivate amitriptyline but rather changes its ionization state to facilitate renal elimination.",
      "correct_choice_id": 247144,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23263711700306121/23263711700306121.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/23263711700306121/23263711700306121.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79827,
      "choices": [
        {
          "id": 247146,
          "text": "Before conception, because the drug described is known to cause mutations in the maternal germ cell line"
        },
        {
          "id": 247147,
          "text": "Days 1 to 17 after conception"
        },
        {
          "id": 247148,
          "text": "Days 18 to 55 after conception"
        },
        {
          "id": 247149,
          "text": "Days 56 to birth"
        }
      ],
      "text": "A 21-year-old pregnant female asks her doctor what she can do about her acne. The doctor prescribes a topical benzoyl peroxide preparation, but the patient is unsatisfied with the results. She has a close friend taking a vitamin A–based acne control product, and her friend often tells her how well it works. She begins taking her friend’s pills and is pleased with the reduction in her acne. During which prenatal period is her unborn child at greatest risk for developing a birth defect?",
      "unique_key": "Q5161154",
      "question_audio": null,
      "question_video": null,
      "map_id": 34133600,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Days 18 to 55 after conception Explanation for the Correct Answer: The most critical period for teratogenic effects of vitamin A-based drugs, such as isotretinoin, occurs during days 18 to 55 after conception. This period corresponds to organogenesis, when the major organs, including the heart, brain, and facial structures, are developing. Isotretinoin and other retinoids are potent teratogens that can cause severe congenital malformations, including: Craniofacial defects (e.g., cleft palate, microcephaly) Cardiac anomalies (e.g., conotruncal malformations) CNS abnormalities (e.g., hydrocephalus, intellectual disabilities) Thymic aplasia Since organogenesis primarily occurs during weeks 3 to 8 of gestation (days 18 to 55), this is the period of greatest risk for birth defects if a teratogenic drug is taken. Thus, option (C) is correct because exposure to retinoids during this window can cause severe congenital malformations. Explanation for the Incorrect Answers: (A) Before conception, because the drug described is known to cause mutations in the maternal germ cell line Retinoids do not induce mutations in the maternal germ cells. Instead, their teratogenic effects result from direct interference with embryonic development, particularly neural crest cell migration and Hox gene regulation. While preconception exposure does not cause birth defects, retinoids have a long half-life, and women are advised to stop taking them at least one month before conception to avoid teratogenic effects. Since teratogenic effects require fetal exposure, this answer is incorrect. (B) Days 1 to 17 after conception The pre-implantation period (days 1–17) follows an “all-or-none” response to teratogenic exposure: Either the embryo dies (spontaneous abortion), or it survives without defects due to compensatory mechanisms. Since organogenesis has not yet started, structural birth defects are unlikely if exposure occurs in this period. However, continued use beyond day 18 increases the risk of congenital anomalies. This period is not the highest risk for teratogenic malformations, making (B) incorrect. (D) Days 56 to birth After organogenesis is complete (week 9 onward), the fetus undergoes growth and maturation rather than major structural development. Exposure to teratogens at this stage typically causes functional abnormalities (e.g., neurodevelopmental delay) rather than structural defects. Retinoid exposure after day 56 is still harmful but does not pose as high a risk for severe congenital malformations as during days 18–55. This answer is incorrect because the most critical period for birth defects is during organogenesis, not the fetal period.",
      "correct_choice_id": 247148,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53805371700306136/53805371700306136.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53805371700306136/53805371700306136.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79828,
      "choices": [
        {
          "id": 247150,
          "text": "Hypoglycemia"
        },
        {
          "id": 247151,
          "text": "Osteoporosis"
        },
        {
          "id": 247152,
          "text": "Hypertension"
        },
        {
          "id": 247153,
          "text": "Bradycardia"
        }
      ],
      "text": "Which adverse effect is associated with long-term use of corticosteroids?",
      "unique_key": "Q8618821",
      "question_audio": null,
      "question_video": null,
      "map_id": 34507635,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Osteoporosis. Long-term use of corticosteroids, such as prednisone and dexamethasone, is strongly associated with osteoporosis, a condition characterized by decreased bone mineral density and increased fracture risk. Corticosteroids inhibit osteoblast activity (bone formation) and promote osteoclast activity (bone resorption), leading to bone loss over time. Additionally, they reduce calcium absorption from the gut and increase calcium excretion in the urine, contributing to secondary hyperparathyroidism, which further accelerates bone resorption. The risk is especially high in postmenopausal women and elderly patients. Long-term corticosteroid therapy can lead to fragility fractures, particularly in the vertebrae and hips, making osteoporosis a significant concern in chronic users. To mitigate this risk, patients on long-term corticosteroids are often advised to take calcium, vitamin D supplements, bisphosphonates, or engage in weight-bearing exercises to maintain bone health. Explanation of Incorrect Options: (A) Hypoglycemia – This is incorrect because corticosteroids generally cause hyperglycemia, not hypoglycemia. Corticosteroids induce insulin resistance and promote gluconeogenesis (glucose production) in the liver, which can lead to steroid-induced diabetes in some patients, particularly those predisposed to metabolic disorders. Thus, corticosteroids do not cause hypoglycemia, making this answer incorrect. (C) Hypertension – While corticosteroids can increase blood pressure due to sodium and fluid retention via mineralocorticoid activity, the most severe and well-established chronic adverse effect is osteoporosis rather than hypertension. The hypertensive effect may contribute to cardiovascular risks but is not the primary concern in long-term corticosteroid use compared to bone loss. (D) Bradycardia – Corticosteroids are not associated with bradycardia (slow heart rate). In some cases, they may even cause tachycardia (fast heart rate) due to their metabolic effects, increased blood pressure, and potential hypokalemia (potassium loss). Therefore, this is not a recognized adverse effect of long-term corticosteroid use.",
      "correct_choice_id": 247151,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66884961727531803/66884961727531803.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/66884961727531803/66884961727531803.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79829,
      "choices": [
        {
          "id": 247154,
          "text": "Pharmacodynamic interaction"
        },
        {
          "id": 247155,
          "text": "Pharmacokinetic interaction"
        },
        {
          "id": 247156,
          "text": "Therapeutic interaction"
        },
        {
          "id": 247157,
          "text": "Adverse interaction"
        }
      ],
      "text": "Which type of drug interaction occurs when one drug alters the metabolism of another drug in the liver?",
      "unique_key": "Q3344460",
      "question_audio": null,
      "question_video": null,
      "map_id": 34567761,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Pharmacokinetic interaction. Pharmacokinetic interactions occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. In this case, when one drug alters the metabolism of another drug in the liver, it is specifically influencing the metabolism phase of pharmacokinetics. This typically happens through the cytochrome P450 (CYP) enzyme system, where a drug may act as an enzyme inducer (increasing metabolism, leading to reduced drug levels and efficacy) or an enzyme inhibitor (decreasing metabolism, leading to increased drug levels and potential toxicity). For example: Enzyme Induction: Rifampin, carbamazepine, or phenytoin induce CYP enzymes, increasing the metabolism of drugs like warfarin, leading to reduced anticoagulant effects. Enzyme Inhibition: Macrolide antibiotics (e.g., erythromycin), azole antifungals, and grapefruit juice inhibit CYP enzymes, decreasing the metabolism of drugs like statins, leading to increased drug levels and a higher risk of toxicity. Explanation of Incorrect Options: (A) Pharmacodynamic interaction – Pharmacodynamic interactions occur when two drugs interact at the same receptor site or physiological pathway, affecting the drug’s effect (response) rather than metabolism. Examples include synergistic effects (e.g., benzodiazepines and opioids causing excessive sedation) or antagonistic effects (e.g., beta-blockers counteracting beta-agonist bronchodilators). Since the question focuses on metabolism, this is incorrect. (C) Therapeutic interaction – This term is not commonly used in pharmacological classifications. While some drug interactions can enhance therapeutic effects (e.g., combining two antihypertensives for better blood pressure control), the question specifically asks about drug metabolism, which is a pharmacokinetic process. Therefore, this option is incorrect. (D) Adverse interaction – While altering drug metabolism can lead to adverse effects (e.g., toxicity or therapeutic failure), the term \"adverse interaction\" is a broad and nonspecific category rather than a distinct type of interaction. Pharmacokinetic interactions may or may not result in adverse outcomes, making this answer less precise.",
      "correct_choice_id": 247155,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15184081727531872/15184081727531872.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15184081727531872/15184081727531872.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79830,
      "choices": [
        {
          "id": 247158,
          "text": "ED50"
        },
        {
          "id": 247159,
          "text": "LD50"
        },
        {
          "id": 247160,
          "text": "TD50"
        },
        {
          "id": 247161,
          "text": "EC50"
        }
      ],
      "text": "What is the term for the dose of a drug that produces a therapeutic effect in 50% of the population?",
      "unique_key": "Q8277152",
      "question_audio": null,
      "question_video": null,
      "map_id": 34439504,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) ED50. ED50 (Effective Dose 50%) is the dose of a drug that produces a therapeutic effect in 50% of the population. It is a key parameter in pharmacology and is used to assess drug potency. A lower ED50 indicates a more potent drug because a smaller dose is required to achieve the desired effect. ED50 is determined through dose-response studies and helps establish the drug’s therapeutic window, ensuring that an effective dose is given while minimizing adverse effects. It is also crucial in drug development and regulatory approval, as it helps define standard dosing recommendations. Explanation of Incorrect Options: (B) LD50 – LD50 (Lethal Dose 50%) is the dose of a drug that causes death in 50% of a tested population (usually in animal studies). It is used to assess drug toxicity and safety margins, but it does not measure therapeutic effects. LD50 is important for determining the therapeutic index (TI = LD50/ED50), which indicates the safety of a drug. A high therapeutic index suggests a safer drug, whereas a low therapeutic index means there is a narrow margin between an effective dose and a lethal dose. (C) TD50 – TD50 (Toxic Dose 50%) is the dose at which 50% of the population experiences toxic effects. Unlike LD50, TD50 refers to non-lethal toxic effects such as nausea, hepatotoxicity, or kidney damage. This value is crucial for understanding dose-dependent toxicity and helps define a drug’s safety profile. While TD50 is useful for risk assessment, it does not indicate the dose required for therapeutic efficacy, making it incorrect in this context. (D) EC50 – EC50 (Effective Concentration 50%) is the concentration of a drug that produces 50% of its maximum effect in an in vitro (lab-based) system rather than in a whole population. EC50 is commonly used in receptor-binding studies and pharmacodynamics but differs from ED50, which is based on population responses rather than drug concentration in a controlled environment.",
      "correct_choice_id": 247158,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78196951727531903/78196951727531903.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/78196951727531903/78196951727531903.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79831,
      "choices": [
        {
          "id": 247162,
          "text": "Phase I"
        },
        {
          "id": 247163,
          "text": "Phase II"
        },
        {
          "id": 247164,
          "text": "Phase III"
        },
        {
          "id": 247165,
          "text": "Phase IV"
        }
      ],
      "text": "Which phase of a clinical trial is primarily concerned with the assessment of the drug’s efficacy and side effects in a larger patient population?",
      "unique_key": "Q1215534",
      "question_audio": null,
      "question_video": null,
      "map_id": 34117519,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Phase III. Phase III clinical trials are primarily focused on assessing the efficacy and safety of a drug in a large patient population. These trials involve hundreds to thousands of participants and are conducted in multiple clinical settings. The goal is to confirm the drug's therapeutic benefits, compare it with existing treatments or placebos, and identify potential side effects. Phase III trials provide the critical data required for regulatory approval by agencies like the FDA (U.S.) or EMA (Europe). If successful, the drug can proceed to market approval and post-marketing surveillance. Explanation of Incorrect Options: (A) Phase I This is incorrect because Phase I trials focus mainly on evaluating the safety, tolerability, and pharmacokinetics of a drug in a small group (20–100) of healthy volunteers or patients. The primary goal is to determine the appropriate dosage range and identify any early adverse effects, rather than assessing efficacy in a large patient population. (B) Phase II While Phase II trials do evaluate both efficacy and safety, they are conducted in a smaller group of patients (100–300). This phase serves as a preliminary assessment of the drug’s effectiveness for a specific condition, helping to determine the optimal dosing regimen. However, the study size is not large enough to fully assess the drug's safety profile and long-term effects. (D) Phase IV This option is incorrect because Phase IV trials occur after a drug has been approved and marketed. These post-marketing surveillance studies monitor long-term safety, rare adverse effects, and real-world effectiveness in the general population. While they assess safety and efficacy, they are not the primary phase for establishing efficacy in a large patient population before approval.",
      "correct_choice_id": 247164,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79832,
      "choices": [
        {
          "id": 247166,
          "text": "Side effect"
        },
        {
          "id": 247167,
          "text": "Drug interaction"
        },
        {
          "id": 247168,
          "text": "Adverse reaction"
        },
        {
          "id": 247169,
          "text": "Therapeutic effect"
        }
      ],
      "text": "What is the term for an unexpected or abnormal reaction to a drug that is different from its intended effect?",
      "unique_key": "Q8363431",
      "question_audio": null,
      "question_video": null,
      "map_id": 34575938,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Adverse reaction. An adverse drug reaction (ADR) is an unexpected, abnormal, or harmful response to a drug that occurs at normal doses used for treatment. Unlike side effects, which are often predictable and sometimes mild, adverse reactions can be severe, unpredictable, and potentially life-threatening. These reactions may result from hypersensitivity (allergic reactions), genetic factors, or unknown mechanisms. For example, Stevens-Johnson syndrome from certain antibiotics or anaphylaxis from penicillin are severe adverse drug reactions. Explanation of Incorrect Options: (A) Side effect A side effect refers to a predictable but unintended effect of a drug that occurs at normal therapeutic doses. While side effects can be bothersome (e.g., drowsiness from antihistamines), they are usually less severe and do not require stopping the drug. Adverse reactions, on the other hand, can be more serious and may require immediate medical intervention. (B) Drug interaction This is incorrect because a drug interaction occurs when one drug alters the effect of another drug, either by enhancing or reducing its action. Drug interactions can be pharmacokinetic (affecting absorption, metabolism, or excretion) or pharmacodynamic (altering the drug’s effect at the receptor level). While interactions may cause adverse effects, they are not the same as an unexpected abnormal reaction to a single drug. (D) Therapeutic effect The therapeutic effect is the intended or desired effect of a drug, such as pain relief from an analgesic or blood pressure reduction from an antihypertensive. Since an adverse reaction is an undesired and harmful effect, this option is incorrect.",
      "correct_choice_id": 247168,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43687501727532061/43687501727532061.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/43687501727532061/43687501727532061.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79833,
      "choices": [
        {
          "id": 247170,
          "text": "It refers to the study of drug effects on the body"
        },
        {
          "id": 247171,
          "text": "It includes absorption, distribution, metabolism, and excretion of drugs"
        },
        {
          "id": 247172,
          "text": "It solely focuses on the therapeutic effects of drugs"
        },
        {
          "id": 247173,
          "text": "It is the study of how drugs bind to their receptors"
        }
      ],
      "text": "Which of the following statements about pharmacokinetics is true?",
      "unique_key": "Q9858505",
      "question_audio": null,
      "question_video": null,
      "map_id": 34621722,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) It includes absorption, distribution, metabolism, and excretion of drugs. Pharmacokinetics (PK) refers to the study of how a drug moves through the body over time. It involves four key processes: Absorption – How the drug enters the bloodstream after administration (e.g., oral drugs absorbed through the intestines). Distribution – How the drug is transported to different tissues and organs via the bloodstream. Metabolism – How the drug is chemically altered, mainly in the liver, to either activate or deactivate it. Excretion – How the drug and its metabolites are eliminated, primarily through the kidneys (urine) or bile (feces). Understanding pharmacokinetics helps in determining the dosage, frequency, and route of administration to optimize drug effectiveness while minimizing toxicity. Explanation of Incorrect Options: (A) It refers to the study of drug effects on the body This is incorrect because the study of how drugs affect the body is called pharmacodynamics (PD). Pharmacodynamics involves understanding how drugs interact with receptors, enzymes, and cellular mechanisms to produce therapeutic or toxic effects. (C) It solely focuses on the therapeutic effects of drugs This is incorrect because pharmacokinetics is not limited to therapeutic effects—it studies the entire journey of a drug in the body, including metabolism and elimination, which may not necessarily be related to its therapeutic action. (D) It is the study of how drugs bind to their receptors This is incorrect because receptor binding is a key aspect of pharmacodynamics, not pharmacokinetics. Pharmacodynamics examines drug-receptor interactions, signal transduction, and the dose-response relationship, whereas pharmacokinetics focuses on drug movement in the body.",
      "correct_choice_id": 247171,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77705311727532084/77705311727532084.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77705311727532084/77705311727532084.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79834,
      "choices": [
        {
          "id": 247174,
          "text": "Nausea from chemotherapy"
        },
        {
          "id": 247175,
          "text": "Anaphylaxis from penicillin"
        },
        {
          "id": 247176,
          "text": "Drowsiness from antihistamines"
        },
        {
          "id": 247177,
          "text": "Constipation from opioids"
        }
      ],
      "text": "Which of the following adverse drug reactions is classified as a Type B reaction?",
      "unique_key": "Q5266816",
      "question_audio": null,
      "question_video": null,
      "map_id": 34930354,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Anaphylaxis from penicillin. Type B (idiosyncratic or unpredictable) adverse drug reactions (ADRs) are not dose-dependent and occur in a small subset of individuals due to hypersensitivity or genetic factors. These reactions are typically immune-mediated (e.g., allergic reactions) or due to unusual metabolic pathways. Anaphylaxis, a severe allergic reaction to penicillin, is a classic example of a Type B ADR. It occurs due to an immune system overreaction leading to symptoms like difficulty breathing, swelling, and shock. Since these reactions are not predictable from the drug’s known pharmacological effects, they fall under Type B ADRs. Explanation of Incorrect Options: (A) Nausea from chemotherapy This is incorrect because nausea is a predictable side effect of chemotherapy, related to its mechanism of action. Type A ADRs (dose-dependent and predictable reactions) are more common and result from the pharmacological properties of the drug, such as the toxic effects of chemotherapy on rapidly dividing cells. (C) Drowsiness from antihistamines This is also incorrect because drowsiness is a known pharmacological effect of first-generation antihistamines (e.g., diphenhydramine). It is dose-dependent and an expected Type A ADR, as these drugs cross the blood-brain barrier and block histamine receptors in the central nervous system. (D) Constipation from opioids This is incorrect because opioid-induced constipation is a well-known, predictable side effect caused by the drug’s action on opioid receptors in the gastrointestinal tract. This makes it a Type A ADR, as it results from the expected pharmacological activity of opioids.",
      "correct_choice_id": 247175,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45413401727532124/45413401727532124.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/45413401727532124/45413401727532124.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79835,
      "choices": [
        {
          "id": 247178,
          "text": "A higher TI indicates a greater risk of toxicity"
        },
        {
          "id": 247179,
          "text": "TI is the ratio of the toxic dose to the effective dose"
        },
        {
          "id": 247180,
          "text": "TI is always a fixed value for a given drug"
        },
        {
          "id": 247181,
          "text": "A lower TI indicates a safer drug"
        }
      ],
      "text": "Which of the following statements about the therapeutic index (TI) is TRUE?",
      "unique_key": "Q6614873",
      "question_audio": null,
      "question_video": null,
      "map_id": 34841985,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) TI is the ratio of the toxic dose to the effective dose. The therapeutic index (TI) is a measure of a drug’s safety margin, defined as the ratio between the toxic dose (TD50 or LD50) and the effective dose (ED50): TI = TD50 / ED50 TD50 (toxic dose in 50% of the population) or LD50 (lethal dose in 50% of animals) represents the dose that produces toxic or lethal effects. • ED50 is the dose that produces the desired therapeutic effect in 50% of the population. A higher TI means a drug has a wider safety margin because the toxic dose is much higher than the effective dose (e.g., penicillin has a high TI). Conversely, a lower TI means a narrow safety margin, requiring careful dosing (e.g., warfarin, digoxin, lithium). Explanation of Incorrect Options: (A) A higher TI indicates a greater risk of toxicity This is incorrect because a higher TI actually means a drug is safer, as there is a large difference between the effective and toxic doses. For example, drugs like penicillin and benzodiazepines have a high TI, making overdose less likely. In contrast, drugs with a low TI (e.g., chemotherapy drugs, warfarin) require close monitoring due to a higher risk of toxicity. (C) TI is always a fixed value for a given drug This is incorrect because TI can vary between individuals due to age, genetics, liver and kidney function, and drug interactions. A drug's therapeutic window may differ based on patient-specific factors, making dosing adjustments necessary in certain populations (e.g., elderly or renal-impaired patients). (D) A lower TI indicates a safer drug This is incorrect because a lower TI means a drug has a narrow margin between therapeutic and toxic doses, increasing the risk of overdose or toxicity. For example, digoxin and lithium have a low TI, meaning even small dose variations can cause toxicity. Drugs with a high TI (e.g., paracetamol at therapeutic doses) are generally safer.",
      "correct_choice_id": 247179,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13668551727532268/13668551727532268.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13668551727532268/13668551727532268.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79836,
      "choices": [
        {
          "id": 247182,
          "text": "Patient satisfaction"
        },
        {
          "id": 247183,
          "text": "Quality of life"
        },
        {
          "id": 247184,
          "text": "Pharmacokinetic parameters"
        },
        {
          "id": 247185,
          "text": "All of the above"
        }
      ],
      "text": "Which of the following is a common outcome measured in clinical trials?",
      "unique_key": "Q2358786",
      "question_audio": null,
      "question_video": null,
      "map_id": 34028182,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. In clinical trials, multiple outcome measures are used to assess a drug’s efficacy, safety, and overall impact on patients. These outcomes can be clinical, subjective, or pharmacokinetic, depending on the trial’s objectives. Patient satisfaction – This is an important measure in clinical trials, especially for chronic conditions and long-term therapies. Patient satisfaction helps assess treatment acceptability, adherence, and perceived benefits. It is often evaluated through surveys, questionnaires, and patient-reported outcomes (PROs). Quality of life (QoL) – Clinical trials often measure how a treatment affects a patient’s overall well-being, particularly in chronic diseases like cancer, diabetes, and cardiovascular conditions. QoL assessments include factors such as physical health, emotional well-being, social functioning, and mental health. Standardized tools like the SF-36 (Short Form Health Survey) or EQ-5D are commonly used. Pharmacokinetic parameters – These include absorption, distribution, metabolism, and excretion (ADME) of a drug, measured using parameters like Cmax (maximum concentration), Tmax (time to peak concentration), half-life (t?/?), and AUC (area under the curve). These outcomes are crucial for determining dosing regimens and drug interactions. Explanation of Incorrect Options: (A) Patient satisfaction This is incorrect as a standalone answer because, while important for assessing adherence and treatment acceptability, patient satisfaction alone does not provide complete clinical trial data. It must be combined with objective measures like efficacy and safety. (B) Quality of life This is incorrect alone because QoL, while a critical component in many trials, does not directly measure drug efficacy or pharmacokinetics. QoL assessments are especially important in chronic disease management and palliative care. (C) Pharmacokinetic parameters This is incorrect alone because pharmacokinetic studies help determine the drug’s behavior in the body but do not assess subjective patient experiences like satisfaction and quality of life. Pharmacokinetics is especially relevant in Phase I and Phase II trials.",
      "correct_choice_id": 247185,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67097511727532315/67097511727532315.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/67097511727532315/67097511727532315.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 79837,
      "choices": [
        {
          "id": 247186,
          "text": "To approve the marketing of drugs"
        },
        {
          "id": 247187,
          "text": "To ensure the safety and ethical treatment of study participants"
        },
        {
          "id": 247188,
          "text": "To conduct the clinical trials"
        },
        {
          "id": 247189,
          "text": "To monitor drug interactions in patients"
        }
      ],
      "text": "What is the primary role of the Institutional Review Board (IRB) in clinical research?",
      "unique_key": "Q4900196",
      "question_audio": null,
      "question_video": null,
      "map_id": 34729032,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) To ensure the safety and ethical treatment of study participants. The Institutional Review Board (IRB) is an independent committee responsible for reviewing and approving clinical research to protect the rights, welfare, and safety of human participants. It ensures that studies comply with ethical principles, federal regulations, and institutional policies. Key functions of the IRB include: Reviewing study protocols to assess risks and benefits. Ensuring informed consent is properly obtained from participants. Monitoring ongoing trials for compliance and safety concerns. Ensuring ethical treatment in accordance with the Declaration of Helsinki, Belmont Report, and Good Clinical Practice (GCP) guidelines. IRBs play a crucial role in safeguarding vulnerable populations, such as children, pregnant women, and prisoners, ensuring that research is scientifically valid and ethically conducted. Explanation of Incorrect Options: (A) To approve the marketing of drugs This is incorrect because drug marketing approval falls under the jurisdiction of regulatory agencies like the FDA (U.S.), EMA (Europe), and CDSCO (India). The IRB does not evaluate whether a drug should be marketed; instead, it reviews clinical trials before and during research to ensure ethical standards are met. (C) To conduct the clinical trials This is incorrect because clinical trials are conducted by research investigators, sponsors, and clinical research organizations (CROs). The IRB does not directly run clinical trials; rather, it reviews and oversees them to ensure ethical compliance. (D) To monitor drug interactions in patients This is incorrect because drug interactions are studied in clinical pharmacology and post-marketing surveillance, usually by clinical investigators, pharmacists, and regulatory agencies. The IRB does not focus on drug interactions; instead, it ensures that research participants are not exposed to undue risks.",
      "correct_choice_id": 247187,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65135141727532339/65135141727532339.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/65135141727532339/65135141727532339.m3u8",
      "question_images": [],
      "explanation_images": []
    }
  ]
}